Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
- Press Release
- Source: Novavax, Inc.
- On 12:33 pm EDT, Friday October 30, 2009
ROCKVILLE, Md., Oct 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) today announced that it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, November 6, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, November 6, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 814-8448 (International: 1 (703) 639-1367.
Related Quotes
| Symbol | Price | Change |
|---|---|---|
| NVAX | 3.20 | 0.00 |
A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning November 6, 2009 at 1:00 pm through November 8, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1394584.
About Novavax, Inc.
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com
Related Headlines
- Novavax to Hold Public Offering of Common Stock - at Fox Business
- NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement - EDGAR Online
- Novavax plans offering of 6.8M shares; stock falls - AP
- Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst - Wall Street Transcript
- Novavax Prices Public Offering of Common Stock - PR Newswire
Related Blog Headlines
- CDC Sticking with 'Tried and True' Methods for Flu Vaccines - at Seeking Alpha
- Monday Options Recap - at Seeking Alpha
- A Mixed Bag for Traders and Investors in Healthcare - at Seeking Alpha
- Swine Flu Stocks: Where Are They Now? - at Seeking Alpha
- Healthcare Takeover Talk Continues - at Seeking Alpha
Sponsored Links
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Super Cheap Car Insurance Quotes
Get Discount Auto Insurance Quotes Online - Rates from $15 / Month. -
Need Affordable Health Care?
Get Affordable Health Insurance Quotes Online - Rates from $30 / Month
Tech Ticker Recent Posts
- Housing Bottom? "Not Even Close," Barry Ritholtz Says - Aaron Task
- A Bad Economy Could Spell Good News on Wall Street for Years to Come - Peter Gorenstein
- The FDIC Is $8.2 Billion in the Hole - John Carney
Add Alert Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.